Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

The 3‐year placebo‐controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the antifracture efficacy of denosumab in postmenopausal women with osteoporosis. The 7‐year open‐label extension demonstrated that denosumab treatment for up to 10 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Siris, Ethel, McDermott, Michele, Pannacciulli, Nicola, Miller, Paul D, Lewiecki, E Michael, Chapurlat, Roland, Jódar‐Gimeno, Esteban, Huang, Shuang, Kanis, John A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117843/
https://www.ncbi.nlm.nih.gov/pubmed/32258966
http://dx.doi.org/10.1002/jbm4.10348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117843/
https://www.ncbi.nlm.nih.gov/pubmed/32258966
http://dx.doi.org/10.1002/jbm4.10348

Ejemplares similares